Our core provides CFAR laboratory researchers with access to cutting-edge and novel molecular profiling technologies experiments, including high-throughput sequencing of host or pathogen DNA or RNA, mass spectrometry assays of proteins or metabolites, or experiments that integrate many of these data types together. The diversity of molecular profiling technologies and research questions that can lead from them often require idiosyncratic domain-specific expertise in order to design experiments and then to process and interpret the resulting data. These skills alone or together are rarely found in a single CFAR researcher laboratory funded by traditional sources. The MPCB core will allow CFAR researchers to circumvent these and other barriers, allowing them to undertake new and innovative research directions. A priority of the MPCB core will be to support new investigators, whether they are young investigators or established researchers who are newly using profiling technologies in their research, especially those who are developing preliminary work for independent funding.
Aim 1 : To provide services for experimental design, data processing, and data interpretation for experiments that profile human cells and tissues, viruses, and/or microbiome communities.
Aim 2 : To develop and disseminate new high-impact HIV relevant computational capabilities to CFAR investigators.
Aim 3 : To disseminate expertise into the CFAR community through formal classroom training. Our core services, faculty, staff and leadership model are new, and represents an evolution of a previous core in response to new opportunities and needs among laboratory-based HIV/Aids researchers.
|Stekler, Joanne D; McKernan, Jennifer; Milne, Ross et al. (2015) Lack of resistance to integrase inhibitors among antiretroviral-naive subjects with primary HIV-1 infection, 2007-2013. Antivir Ther 20:77-80|
|Mohanraj, Rani; Jeyaseelan, Visalakshi; Kumar, Shuba et al. (2015) Cultural adaptation of the Brief COPE for persons living with HIV/AIDS in southern India. AIDS Behav 19:341-51|
|Slyker, Jennifer A; Casper, Corey; Tapia, Kenneth et al. (2014) Accelerated suppression of primary Epstein-Barr virus infection in HIV-infected infants initiating lopinavir/ritonavir-based versus nevirapine-based combination antiretroviral therapy. Clin Infect Dis 58:1333-7|
|Mackelprang, Romel D; Bigham, Abigail W; Celum, Connie et al. (2014) Toll-like receptor polymorphism associations with HIV-1 outcomes among sub-Saharan Africans. J Infect Dis 209:1623-7|
|Gantt, Soren; Cattamanchi, Ashok; Krantz, Elizabeth et al. (2014) Reduced human herpesvirus-8 oropharyngeal shedding associated with protease inhibitor-based antiretroviral therapy. J Clin Virol 60:127-32|
|Puttkammer, Nancy H; Zeliadt, Steven B; Balan, Jean Gabriel et al. (2014) Before and after the earthquake: a case study of attrition from the HIV antiretroviral therapy program in Haiti. Glob Health Action 7:24572|
|Gerdts, Sarah E; Wagenaar, Bradley H; Micek, Mark A et al. (2014) Linkage to HIV care and antiretroviral therapy by HIV testing service type in Central Mozambique: a retrospective cohort study. J Acquir Immune Defic Syndr 66:e37-44|
|Liu, Yi; Rao, Ushnal; McClure, Jan et al. (2014) Impact of mutations in highly conserved amino acids of the HIV-1 Gag-p24 and Env-gp120 proteins on viral replication in different genetic backgrounds. PLoS One 9:e94240|
|Chung, Michael H; Beck, Ingrid A; Dross, Sandra et al. (2014) Oligonucleotide ligation assay detects HIV drug resistance associated with virologic failure among antiretroviral-naive adults in Kenya. J Acquir Immune Defic Syndr 67:246-53|
|Pantalone, David W; Huh, David; Nelson, Kimberly M et al. (2014) Prospective predictors of unprotected anal intercourse among HIV-seropositive men who have sex with men initiating antiretroviral therapy. AIDS Behav 18:78-87|
Showing the most recent 10 out of 552 publications